Fruquintinib plus sintilimab in patients with advanced renal cell carcinoma: results from a phase 2 clinical trial
讲者：叶定伟
单位：复旦大学附属肿瘤医院
Fruquintinib plus sintilimab in patients with advanced endometrial cancer: a multicentre, open-label, single-arm, phase 2 clinical trial
讲者：吴小华
HER2/PD-1双特异性抗体IBI315在HER2表达的实体肿瘤患者Ia期剂量递增研究的初步结果
讲者：胡夕春
Phase Ib study of the CDK4/6 inhibitor, FCN-437c in combination with letrozole, in Chinese patients with HR+/HER2- advanced breast cancer (ABC)
评估TAA013在复发型HER2阳性乳腺癌患者的安全性、耐受性及药动学/药效学的I期临床研究
讲者：殷咏梅
单位：江苏省人民医院
2021版肿瘤相关性贫血指南解读
讲者：张明智
单位：郑州大学第一附属医院
规范管理PARP抑制剂血小板减少
讲者：居杏珠
A phase 2 study of fruquintinib plus sintilimab in pretreated patients with advanced hepatocellular carcinoma
讲者：秦叔逵
单位：东部战区总医院
同步放化疗血小板减少的临床管理
讲者：杨坤禹
单位：华中科技大学同济医学院附属协和医院
Updated patient-reported outcomes (PROs) with atezolizumab (atezo) + bevacizumab (bev) vs sorafenib (sor) in Chinese patients (pts) with unresectable HCC in IMbrave150
